Boundless Bio is a precision oncology company developing ecDNA-directed therapies (ecDTx) to target oncogene amplified cancers, which affect over 5 million patients annually and currently lack effective treatment options. By leveraging their proprietary Spyglass platform, Boundless Bio identifies and exploits the vulnerabilities associated with extrachromosomal DNA, a key mechanism driving tumor growth and resistance to existing therapies.
Funding
$100M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
LBFounders
Product
Problem
Oncogene amplified cancers, affecting over 5 million patients annually, currently lack effective treatment options, leading to poor prognosis and survival rates. Existing targeted therapies and immunotherapies have proven largely ineffective against cancers driven by oncogene amplification.
Solution
Boundless Bio is a clinical-stage precision oncology company pioneering ecDNA-directed therapies (ecDTx) to address oncogene amplified cancers. The company's approach leverages the unique vulnerabilities associated with extrachromosomal DNA (ecDNA), a key mechanism driving tumor growth, evolution, and resistance to existing treatments. Boundless Bio's proprietary Spyglass platform identifies and exploits cancer-specific liabilities that arise from cancer cells' reliance on ecDNA. By targeting ecDNA, Boundless Bio aims to develop novel cancer medicines that eliminate cancer cells' ability to survive and proliferate.
Target Audience
The primary target audience includes patients with oncogene amplified cancers and the healthcare professionals who treat them, including oncologists and clinical researchers.
Features
- Proprietary Spyglass platform for identifying cancer-specific liabilities associated with ecDNA.
- Development of ecDNA-directed therapies (ecDTx) designed to target and disrupt ecDNA function in cancer cells.
- Focus on oncogene amplified cancers, a subset of cancers with limited treatment options.
- Aims to develop therapies that prevent cancer cells from using ecDNA to survive and proliferate.